Ruanyun Edai signs deal to license Cogni AI platform exclusively to BioNexus Gene Lab in Malaysian healthcare
Bitget2026/10/05 13:12Ruanyun Edai Technology signed a definitive deal to license its Cogni AI platform exclusively for Malaysian healthcare to BioNexus Gene Lab. License runs 10 years from closing, renewable up to 20 years; RYET earns a 10% royalty on qualifying technology receipts. BioNexus will issue 410,000 shares for the license, valued contractually at USD 3.5 million, settled in stock at closing. Separate share exchange gives RYET 150,000 additional BioNexus shares for 500,000 new RYET ordinary shares; no cash consideration. Closing is pending conditions; either side can walk if not closed by March 31, 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ruanyun Edai Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839531) on October 05, 2026, and is solely responsible for the information contained therein.
- Ruanyun Edai Technology signed a definitive deal to license its Cogni AI platform exclusively for Malaysian healthcare to BioNexus Gene Lab.
- License runs 10 years from closing, renewable up to 20 years; RYET earns a 10% royalty on qualifying technology receipts.
- BioNexus will issue 410,000 shares for the license, valued contractually at USD 3.5 million, settled in stock at closing.
- Separate share exchange gives RYET 150,000 additional BioNexus shares for 500,000 new RYET ordinary shares; no cash consideration.
- Closing is pending conditions; either side can walk if not closed by March 31, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
